Pexidartinib (PLX3397)
商品编号:
TS0214
备注:
如需更大包装,请联系销售人员,大包装有极大的折扣优惠!
详细介绍
l 基本信息 |
产品名称 | Pexidartinib (PLX3397) |
一般描述 | Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3. |
别 称 | 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine |
纯 度 | ≥98.0%(HPLC) | CAS NO. | 1029044-16-3 |
分子式 | C20H15ClF3N5 | 分子量 | 417.81 |
适用范围 | 生物试剂,适用于细胞培养等 |
l 理化信息 |
外 观 | 固体 |
溶解性(25℃) | DMSO | ≥50mg/mL |
乙醇 | Insoluble |
水 | Insoluble |
l 生物学信息 |
生物活性/药理作用 | Pexidartinib is a capsule formulation
containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity. Pexidartinib binds to and inhibits phosphorylation of stem cell factor receptor (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), which may result in the inhibition of tumor cell proliferation and
down-modulation of macrophages, osteoclasts and mast cells involved in the osteolytic metastatic disease. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis. Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. |
l 存储 |
存储温度 | -20℃ |
l 注意事项及免责声明 |
本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。 |
l 参考文献 |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |